2022
Hemoglobin normalization outperforms other methods for standardizing dried blood spot metabolomics: A comparative study
Jain A, Morris M, Lin EZ, Khan SA, Ma X, Deziel NC, Godri Pollitt KJ, Johnson CH. Hemoglobin normalization outperforms other methods for standardizing dried blood spot metabolomics: A comparative study. The Science Of The Total Environment 2022, 854: 158716. PMID: 36113793, DOI: 10.1016/j.scitotenv.2022.158716.Peer-Reviewed Original ResearchEvaluation of Racial Disparities in Quality of Care for Patients With Gastrointestinal Tract Cancer Treated With Surgery
Bakkila BF, Kerekes D, Nunez-Smith M, Billingsley KG, Ahuja N, Wang K, Oladele C, Johnson CH, Khan SA. Evaluation of Racial Disparities in Quality of Care for Patients With Gastrointestinal Tract Cancer Treated With Surgery. JAMA Network Open 2022, 5: e225664. PMID: 35377425, PMCID: PMC8980937, DOI: 10.1001/jamanetworkopen.2022.5664.Peer-Reviewed Original ResearchConceptsGastrointestinal tract cancerNegative resection marginsTract cancerNegative surgical marginsBlack patientsAdequate lymphadenectomyWhite patientsQuality of careRacial disparitiesSurgical resectionResection marginsSurgical marginsSurgical careNational Cancer DatabaseRetrospective cohort studySite of cancerLonger median survivalHealth careStandard of careCommon age rangeSignificant racial disparitiesAdjuvant chemotherapyBiliary resectionAdjuvant therapyAdult patients
2021
Kynurenic acid may underlie sex-specific immune responses to COVID-19
Cai Y, Kim DJ, Takahashi T, Broadhurst DI, Yan H, Ma S, Rattray NJW, Casanovas-Massana A, Israelow B, Klein J, Lucas C, Mao T, Moore AJ, Muenker MC, Oh JE, Silva J, Wong P, team Y, Ko AI, Khan SA, Iwasaki A, Johnson CH. Kynurenic acid may underlie sex-specific immune responses to COVID-19. Science Signaling 2021, 14: eabf8483. PMID: 34230210, PMCID: PMC8432948, DOI: 10.1126/scisignal.abf8483.Peer-Reviewed Original ResearchConceptsKynurenic acidImmune responseClinical outcomesSex-specific immune responsesT cell responsesPoor clinical outcomeCOVID-19 patientsCoronavirus disease 2019COVID-19Sex-related differencesMale patientsCytokine abundanceInflammatory cytokinesKynurenine ratioSerum metabolomeDisease 2019Sex-specific linkKynurenine aminotransferaseCell responsesOld malePatientsMalesOutcomesResponseMetabolitesIntratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma
Zhu G, Su H, Johnson CH, Khan SA, Kluger H, Lu L. Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma. European Journal Of Cancer 2021, 151: 25-34. PMID: 33962358, PMCID: PMC8184628, DOI: 10.1016/j.ejca.2021.03.053.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBacteriaBacterial LoadBacterial TranslocationChemokinesClostridialesCytotoxicity, ImmunologicFemaleGastrointestinal MicrobiomeHumansLymphocyte CountLymphocytes, Tumor-InfiltratingMaleMelanomaMiddle AgedPrognosisSkin NeoplasmsT-Lymphocytes, CytotoxicTumor MicroenvironmentYoung AdultConceptsT cellsCutaneous melanomaPatient survivalGut microbiomeAdjusted hazard ratioT cell infiltrationChemokine gene expressionChemokine levelsCytotoxic CD8Hazard ratioSystemic inflammationShorter survivalCCL5 expressionPatient outcomesCD8Immune responseMortality riskGut microbiotaSurvival analysisMelanomaTumor nicheHuman cancersSurvivalSignificant correlationPositive association
2020
Palliative care is underutilized and affects healthcare costs in ruptured abdominal aortic aneurysms
Liu S, Heller DR, Jean RA, Chiu AS, Khan SA, Dardik A. Palliative care is underutilized and affects healthcare costs in ruptured abdominal aortic aneurysms. Surgery 2020, 168: 234-236. PMID: 32139140, PMCID: PMC7748368, DOI: 10.1016/j.surg.2020.01.017.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAortic Aneurysm, AbdominalAortic RuptureCardiopulmonary ResuscitationComorbidityEndovascular ProceduresFemaleHospital ChargesHospital MortalityHumansLength of StayMaleMiddle AgedPalliative CareRenal DialysisRespiration, ArtificialTracheostomyUnited StatesYoung Adult
2019
Digital Inference of Immune Microenvironment Reveals Low-Risk Subtype of Early Lung Adenocarcinoma
Kurbatov V, Balayev A, Saffarzadeh A, Heller DR, Boffa DJ, Blasberg JD, Lu J, Khan SA. Digital Inference of Immune Microenvironment Reveals Low-Risk Subtype of Early Lung Adenocarcinoma. The Annals Of Thoracic Surgery 2019, 109: 343-349. PMID: 31568747, DOI: 10.1016/j.athoracsur.2019.08.050.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma of LungAdultAgedCohort StudiesDatabases, FactualDisease-Free SurvivalFemaleHumansImmunotherapyKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPneumonectomyPrognosisProportional Hazards ModelsRetrospective StudiesRisk AssessmentSurvival AnalysisTumor MicroenvironmentConceptsTumor immune microenvironmentImmune microenvironmentLung adenocarcinomaOverall survivalRisk groupsMast cellsCox proportional hazard modelingEarly-stage lung adenocarcinomaLow-risk subtypesKaplan-Meier analysisPathological staging systemProportional hazard modelingImproved clinical outcomesCancer immune microenvironmentImmune cell typesEarly lung adenocarcinomaActivation stateClinical outcomesValidation cohortMacrophage contentStaging systemMultivariable modelCIBERSORT analysisPatientsClinical decisionPractice Patterns and Guideline Non-Adherence in Surgical Management of Appendiceal Carcinoid Tumors
Heller DR, Jean RA, Luo J, Kurbatov V, Grisotti G, Jacobs D, Chiu AS, Zhang Y, Khan SA. Practice Patterns and Guideline Non-Adherence in Surgical Management of Appendiceal Carcinoid Tumors. Journal Of The American College Of Surgeons 2019, 228: 839-851. PMID: 30898583, PMCID: PMC6751559, DOI: 10.1016/j.jamcollsurg.2019.02.050.Peer-Reviewed Original ResearchConceptsNational Comprehensive Cancer Network guidelinesAge 65 yearsAppendiceal carcinoid tumorsAppendiceal carcinoidsLarge tumorsPractice patternsOverall survivalCarcinoid tumorsSurgical managementNetwork guidelinesProcedure typeSmall tumorsHistory of malignancyNational Cancer DatabaseNational practice patternsMultivariable logistic regressionImpact of guidelinesCox proportional hazardsAggressive resectionLymphovascular invasionClinical factorsTreatment guidelinesTumor sizePatient groupNon-Adherence
2018
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 693-702. PMID: 29891520, DOI: 10.6004/jnccn.2018.0056.Peer-Reviewed Original ResearchConceptsPrimary neuroendocrine tumorNeuroendocrine tumorsAdrenal tumorsManagement of NETsLocoregional advanced diseaseNCCN Guidelines InsightsAdrenal gland tumorsAdvanced diseaseNCCN guidelinesAdult patientsDistant metastasisGastrointestinal tractGland tumorsTumorsNeuroendocrineManagement optionsGuidelinesPatientsPheochromocytomaMetastasisParagangliomaDiseaseTractIntegrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis
Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nature Communications 2018, 9: 1793. PMID: 29728604, PMCID: PMC5935683, DOI: 10.1038/s41467-018-04278-6.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesLiver metastasesColorectal cancerOligometastatic colorectal cancerMetastatic colorectal cancerHigh-risk patientsSubset of patientsClinical risk stratificationTreatment of metastasesAngiogenic signatureVEGFA amplificationOligometastatic stateOverall survivalFavorable survivalRisk stratificationAdverse outcomesMetastatic cancerMolecular subtypesFocal therapyMetastasisPatientsMetastatic virulenceMolecular subtypingRobust subtypesCancer
2017
Predictors of Nonadherence to NCCN Guideline Recommendations for the Management of Stage I Anal Canal Cancer.
Kole AJ, Stahl JM, Park HS, Khan SA, Johung KL. Predictors of Nonadherence to NCCN Guideline Recommendations for the Management of Stage I Anal Canal Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: 355-362. PMID: 28275036, DOI: 10.6004/jnccn.2017.0035.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAnus NeoplasmsCombined Modality TherapyDatabases, FactualDisease ManagementFemaleHumansMaleMedication AdherenceMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioPractice Guidelines as TopicPrognosisProportional Hazards ModelsRisk FactorsTreatment OutcomeConceptsAnal canal cancerAnal cancerNCCN recommendationsSurgical proceduresNCCN Clinical Practice GuidelinesNational Cancer Data BaseGuideline-discordant careAnal canal carcinomaPredictors of nonadherenceClinical practice guidelinesHigh tumor gradeLow-grade tumorsLogistic regression modelingNon-academic facilitiesChi-square testDefinitive chemoradiotherapyGuideline concordantConcurrent chemoradiotherapyAnal carcinomaStandard therapyClinicopathologic factorsGuideline recommendationsMultivariable analysisMale sexTumor size
2016
EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer
Khan SA, Zeng Z, Shia J, Paty PB. EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. Pathology & Oncology Research 2016, 23: 673-677. PMID: 28025786, PMCID: PMC5451302, DOI: 10.1007/s12253-016-0166-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiomarkers, TumorCamptothecinCetuximabColorectal NeoplasmsDNA Mutational AnalysisErbB ReceptorsFemaleGene AmplificationGenes, p53HumansIrinotecanMaleMiddle AgedMutationRas ProteinsConceptsCombination biologic therapyMetastatic colorectal cancerIrinotecan-refractory colorectal cancerRefractory colorectal cancerColorectal cancerEGFR gene amplificationBiologic therapyKRAS mutationsIrinotecan-refractory metastatic colorectal cancerRefractory metastatic colorectal cancerCombination Targeted TherapyGene amplificationPhase II trialEGFR copy numberII trialPredictive biomarkersPredictive markerTargeted therapyTreatment responseBRAF mutationsBevacizumabPatientsCetuximabTumor tissueTherapyColorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients
Khan SA, Morris M, Idrees K, Gimbel MI, Rosenberg S, Zeng Z, Li F, Gan G, Shia J, LaQuaglia MP, Paty PB. Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients. Journal Of Pediatric Surgery 2016, 51: 1812-1817. PMID: 27558481, PMCID: PMC5312708, DOI: 10.1016/j.jpedsurg.2016.07.015.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdolescentAdultAge of OnsetAgedAged, 80 and overBiomarkers, TumorChildColorectal NeoplasmsDNA Mismatch RepairDNA Mutational AnalysisDNA, NeoplasmFemaleHumansMaleMicrosatellite InstabilityMiddle AgedMutationNeoplasm StagingRetrospective StudiesSurvival RateUnited StatesYoung AdultConceptsOnset colorectal cancerEarly-onset colorectal cancerAdult-onset patientsColorectal cancerEarly age onsetPoor prognosisMicrosatellite instabilityOnset patientsClinical dataEarly-age onset colorectal cancerMLH1/PMS2 lossAdult colorectal cancerAdult CRC patientsAdvanced stage presentationMismatch repair expressionHigh-grade cancerAge 30 yearsSpecific genetic subtypesCRC patientsFavorable survivalPMS2 lossGrade cancerBRAF mutationsTumor markersBRAFV600E mutation
2015
Pancreaticoduodenectomy for locally advanced colon cancer in hereditary nonpolyposis colorectal cancer
Zhu R, Grisotti G, Salem RR, Khan SA. Pancreaticoduodenectomy for locally advanced colon cancer in hereditary nonpolyposis colorectal cancer. World Journal Of Surgical Oncology 2015, 14: 12. PMID: 26769110, PMCID: PMC4714509, DOI: 10.1186/s12957-015-0755-7.Peer-Reviewed Original ResearchConceptsNonpolyposis colorectal cancerHereditary nonpolyposis colorectal cancerAdvanced colon cancerColorectal cancerColon cancerBetter long-term outcomesMulti-visceral resectionAdvanced colorectal cancerEarly-stage diseaseRare clinical entityLong-term outcomesSpecial surgical considerationsPaucity of dataAdvanced diseaseStage diseaseMultidisciplinary treatmentSubtotal colectomyPartial colectomyCase presentationWeClinical entitySurgical considerationsLynch syndromeCancerColectomyPancreaticoduodenectomy
2012
Tumor Endothelial Inflammation Predicts Clinical Outcome in Diverse Human Cancers
Pitroda SP, Zhou T, Sweis RF, Filippo M, Labay E, Beckett MA, Mauceri HJ, Liang H, Darga TE, Perakis S, Khan SA, Sutton HG, Zhang W, Khodarev NN, Garcia JG, Weichselbaum RR. Tumor Endothelial Inflammation Predicts Clinical Outcome in Diverse Human Cancers. PLOS ONE 2012, 7: e46104. PMID: 23056240, PMCID: PMC3464251, DOI: 10.1371/journal.pone.0046104.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnimalsBreast NeoplasmsCell Line, TumorCells, CulturedColonic NeoplasmsEndothelial CellsEndothelium, VascularFemaleGene Expression ProfilingGliomaHuman Umbilical Vein Endothelial CellsHumansInflammationKaplan-Meier EstimateLung NeoplasmsMaleMiceMiddle AgedMultivariate AnalysisNeoplasmsNeovascularization, PathologicOligonucleotide Array Sequence AnalysisTumor Necrosis Factor-alphaConceptsEndothelial inflammationEndothelial cellsOverall survivalHuman cancersDiverse human cancersExperimental modelTumor-associated endothelial cellsStromal inflammatory responsePathological prognostic factorsEndothelial-derived factorsPro-inflammatory cytokinesInflammatory gene expressionPathologic tissue specimensUntreated endothelial cellsVascular endothelial cellsMultiple human cancersInflammatory signatureHuman endothelial cellsPrognostic factorsClinical outcomesChronic inflammationInflammatory pathwaysLung cancerTumor necrosisInflammatory response
2010
Improved Testing for Microsatellite Instability in Colorectal Cancer Using a Simplified 3-Marker Assay
Esemuede I, Forslund A, Khan SA, Qin LX, Gimbel MI, Nash GM, Zeng Z, Rosenberg S, Shia J, Barany F, Paty PB. Improved Testing for Microsatellite Instability in Colorectal Cancer Using a Simplified 3-Marker Assay. Annals Of Surgical Oncology 2010, 17: 3370-3378. PMID: 20703819, PMCID: PMC3269820, DOI: 10.1245/s10434-010-1147-4.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdolescentAdultAgedAged, 80 and overBiological AssayBiomarkers, TumorColorectal NeoplasmsComparative Genomic HybridizationDNA RepairDNA Repair EnzymesFemaleFollow-Up StudiesGenetic TestingGerm-Line MutationHumansLymphatic MetastasisMaleMicrosatellite InstabilityMicrosatellite RepeatsMiddle AgedOligonucleotide Array Sequence AnalysisPrognosisProspective StudiesSurvival RateYoung AdultConceptsHereditary nonpolyposis colorectal cancerColorectal cancerMicrosatellite instabilityMSI testingMSI tumorsMismatch repair protein lossBackgroundIn colorectal cancerDisease-specific survivalPredictive scoring systemNonpolyposis colorectal cancerMore BRAF mutationsDefective DNA mismatch repairNCI criteriaFavorable prognosisFavorable survivalKRAS mutationsBRAF mutationsMSI statusDistinct phenotypic propertiesScoring systemCancerValuable markerMSS cancersMethodsDNA samplesProtein loss
2008
Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer
Khan SA, Idrees K, Forslund A, Zeng Z, Rosenberg S, Pincas H, Barany F, Offit K, LaQuaglia MP, Paty PB. Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer. Journal Of Surgical Oncology 2008, 97: 621-625. PMID: 18381604, PMCID: PMC4381874, DOI: 10.1002/jso.20996.Peer-Reviewed Original ResearchConceptsEarly-onset colorectal cancerOnset colorectal cancerColorectal cancerMDM2 SNP309Age 30Germline variantsLi-Fraumeni kindredsP53 genePeripheral blood leukocytesNormal control populationP53 pathway genesFrequency of polymorphismsGermline TP53Blood leukocytesRare diseaseSNP309Control populationTissue availabilityPatientsConstitutional mutationsDisease susceptibilityCancerP53DiseaseGenetic variants